PURPOSE: To report the development and validation of a technique of dual tracer single-photon emission CT brain imaging using technetium-99m hexamethyl-propyleneamine oxime and iodine-123 iodoamphetamine agents and the application of this technique in patients with a variety of diagnoses. METHODS: Contamination between the two isotopes' energy windows was calculated by opening both energy windows while scanning a group of patients using a single isotope. To compare uniformity of I-123 down-scatter, Tc-99m studies were performed both before and after the administration of I-123 in five of 24 dual studies. The 24 patients studied with the dual-isotope technique were evaluated during acetazolamide testing, trial balloon occlusion, or embolization of an arteriovenous malformation. RESULTS: In a dual acquisition, average count contamination of an I-123 study by Tc-99m was less than 1% of the total I-123 counts, and contamination of a Tc-99m study by I-123 was approximately 12% of the total Tc-99m counts. Tc-99m studies performed both before and after the administration of I-123 demonstrated that contaminating counts do not adversely affect scan interpretation. Dual- tracer scans were completed in all 24 patients, 10 of whom showed changes after intervention. CONCLUSIONS: Dual-tracer single-photon emission CT brain scans of adequate diagnostic quality are possible using Tc-99m and I-123.
|Original language||English (US)|
|Number of pages||9|
|Journal||American Journal of Neuroradiology|
|State||Published - Jan 1 1994|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Clinical Neurology